Abiomed continues rebound, expects to file Impella PMA this fiscal year

May 6, 2013 by Brad Perriello

Abiomed CEO Michael Minogue says the company expects to file for pre-market approval from the FDA by the end of fiscal 2014, stressing that it's "business as usual" until then.

Abiomed continues rebound, expects to file Impella PMA by end of fiscal year

Abiomed (NSDQ:ABMD) shares continued their rebound today from a plunge begun late last year after news broke of a federal investigation and new FDA requirements for its flagship Impella heart pump.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp